HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
AbstractAn overactivation of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) axis promotes tumorigenesis and tumor progression in various cancer types. Research data recently evidenced that HGF/MET signaling is also involved also in the immune response, mainly modulating dendritic cells functions. In general, the pathway seems to play an immunosuppressive role, thus hypothesizing that it could constitute a mechanism of primary and acquired resistance to cancer immunotherapy. Recently, some approaches are being developed, including drug design and cell therapy to combine MET and programmed cell death receptor-1 (PD-1)/programmed cell death receptor-ligand 1 (PD-L1) inhibition. This approach could represent a new weapon in cancer therapy in the future. View Full-Text
Share & Cite This Article
Papaccio, F.; Della Corte, C.M.; Viscardi, G.; Di Liello, R.; Esposito, G.; Sparano, F.; Ciardiello, F.; Morgillo, F. HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. Int. J. Mol. Sci. 2018, 19, 3595.
Papaccio F, Della Corte CM, Viscardi G, Di Liello R, Esposito G, Sparano F, Ciardiello F, Morgillo F. HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. International Journal of Molecular Sciences. 2018; 19(11):3595.Chicago/Turabian Style
Papaccio, Federica; Della Corte, Carminia M.; Viscardi, Giuseppe; Di Liello, Raimondo; Esposito, Giovanna; Sparano, Francesca; Ciardiello, Fortunato; Morgillo, Floriana. 2018. "HGF/MET and the Immune System: Relevance for Cancer Immunotherapy." Int. J. Mol. Sci. 19, no. 11: 3595.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.